Zhejiang Shengda Pharm

Shengda Biotech completed its first buyback of 180,000 shares through centralized bidding, representing 0.10% of total share capital. The buyback amount was 1.99 million yuan, with a price range of 10.71 yuan to 10.86 yuan per share. In the first quarter of 2026, the company achieved revenue of 189 million yuan and net profit attributable to shareholders of 13.17 million yuan.

Shengda Bio announced plans to repurchase part of its A-shares through centralized bidding using its own funds or self-raised funds, with a repurchase amount of no less than 16.5 million yuan and no more than 30 million yuan. The maximum repurchase price is 15 yuan per share, and the expected number of shares to be repurchased ranges from 1.1 million to 2 million shares, accounting for 0.58 percent to 1.06 percent of the total share capital. The repurchase period will not exceed 12 months from the date the board of directors approves the plan. In the first quarter of 2026, the company achieved revenue of 189 million yuan and a net profit attributable to the parent company of 13.17 million yuan.

Shengda Bio disclosed plans to use its own funds or self-raised funds to repurchase company shares, with a repurchase amount ranging from 16.5 million yuan to 30 million yuan. The repurchase price will not exceed 15 yuan per share, and the estimated number of shares to be repurchased is approximately 1.1 million to 2 million shares, accounting for about 0.58% to 1.06% of the company's total share capital. The repurchase will be conducted through centralized bidding, and the repurchased shares are intended to serve as the stock source for employee stock ownership plans or equity incentives. The implementation period is within 12 months after approval by the board of directors.